The FDA authorized an updated version of the protein-based Novavax COVID-19 vaccine for use in people 12 and up. Doses could be available by next week.
The FDA authorized an updated version of the protein-based Novavax COVID-19 vaccine for use in people 12 and up. Doses could be available by next week.
